Targeted Natural Killer Cell–Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial - Concepedia

Concepedia

Publication | Open Access

Targeted Natural Killer Cell–Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial

DOI Full Paper Access

60

Citations

33

References

2020

Year

Gabriele Multhoff, Sophie Seier, Stefan Stangl, Wolfgang Sievert, Maxim Shevtsov, Caroline Werner, A. Graham Pockley, Christiane Blankenstein, Martin Hildebrandt, Robert Offner,

Clinical Cancer Research

Abstract

<i>Ex vivo</i> TKD/IL2-activated, autologous NK cells are well tolerated and deliver positive clinical responses in patients with advanced NSCLC after RCT.

References

	Year	Citations

Page 1